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A B S T R A C T
Epilepsy is a common chronic neurological disorder affecting approximately 8 out of 1000 people. Its
pathophysiology, however, has remained elusive in many regards. Consequently, adequate seizure
control is still lacking in about one third of patients. Cytokines are soluble mediators of cell
communication that are critical in immune regulation. In recent years, studies have shown that epileptic
seizures can induce the production of cytokines, which in turn inﬂuence the pathogenesis and course of
epilepsies. At the time of this review, the focus is mostly on interleukin-1beta (IL-1b), interleukin-6 (IL-
6), and tumor necrosis factor alpha (TNFa). In this review, we summarize the current knowledge
regarding these cytokines and their potential roles in epilepsy. The focus concentrates on their
expression and inﬂuence on induced seizures in animal models of epilepsy, as well as ﬁndings in human
studies. Both proconvulsive and anticonvulsive effects have been reported for each of these molecules.
One possible explanation for this phenomenon is that cytokines play dichotomous roles through
multiple pathways, each of which is dependent on free concentration and available receptors.
Furthermore, the immune-mediated leakage in the blood–brain-barrier also plays an important role in
epileptogenesis. Nonetheless, these observations demonstrate the multifarious nature of cytokine
networks and the complex relationship between the immune system and epilepsy. Future studies are
warranted to further clarify the inﬂuence of the immune system on epilepsy and vice versa.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is estimated by theWorld Health Organization to affect
0.8% of the world’s population.1 Although epilepsy is a relatively
common neurological disorder, its etiology and pathophysiology
continue to be elusive in many cases. In recent years, an increasing
body of evidence has indicated that there is a complex relationship
between epilepsy and the immune system. Abnormalities in
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immune system and its associated inﬂammatory reactions seem to
play an important role in epileptogenesis.5–7 Data in this ﬁeld
implicate cytokines as mediators of spontaneous seizures.7–9 This
review provides an overview on the current knowledge of the
relationship between cytokines and epilepsy and focus on the most
commonly studied cytokines IL-1b, IL-6, and TNFa.
2. Interleukin-1 (IL-1)
The IL-1 family comprises three ligands: IL-1a, IL-1b, and IL-
1Ra, all of which bind the IL-1 receptor (IL-1R). IL-1b is mostly
secreted whereas IL-1a is predominantly membrane-bound.10
Consequently, the focus tends to bemore on IL-1b than on IL-1a in
studies regarding the role of cytokines in epilepsy.2,11–13 IL-1Ra is a
protein capable of inhibiting receptor binding and biological
activities of IL-1 without inducing an IL-1-like response.14 IL-1b is
more closely related to IL-1Ra (26% identical amino acids) than it is
to IL-1a (22% identical amino acids).15
IL-1 cytokines are constitutively expressed at very low levels in
the human CNS.3,11 No gross physiological or developmental
defects are shown in IL-1a, IL-1b, or IL-1Ra knockout mice.16,17
However, under certain pathological states IL-1 cytokines are often
elevated in the brain. For example, seizures enhance expression ofvier Ltd. All rights reserved.
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are also reported to be involved in excitotoxicity, oxidative stress
and modulation of neuroendocrine systems.19–22
2.1. Animal studies
Basal levels of IL-1b mRNA and IL-1Ra mRNA are barely
detectable in the intact rat brain.2,11 However, IL-1bmRNA and IL-
1b protein expression rapidly increases in the cortex, hippocam-
pus, and hypothalamus following various experimenter-induced
seizures.2,23–31 In chronic epilepsy animal model, IL-1b expression
is also increased in the cortex and hippocampus.11,23,25,26,32,33 The
cortex and hippocampus showed the most extensive postictal
neuronal injury. In these animal models, at the cellular level, IL-1b
mRNA is ﬁrst expressed by activated microglia followed by
astrocytes.3 IL-1Ra mRNA is observed in similar regions following
induced seizures, but its expression is delayed and not sufﬁcient
for complete inhibition of IL-1 effects.5,26
Most studies suggest proconvulsive effects for IL-1b. In rodent
epilepsy models involving kainic acid, intrahippocampal injection
of IL-1b worsened and prolonged both electrographic and
behavioral seizure activity.5,25 Furthermore, seizure-like behav-
ioral changes induced by whole-cell pertussis vaccine were
signiﬁcantly reduced following inhibition of IL-1b production by
the administration of an inhibitor of IL-1b-converting enzyme and
were almost completely abrogated in IL-1 receptor knockout
mice.34Moreover, endogenous IL-1b has been shown to contribute
to the development of febrile seizures (FS).13
As indirect evidence of the proconvulsive effect of IL-1b,
intracerebral injection of IL-Ra reduced behavioral convulsions
induced by bicuculline methiodide in mice.5 In transgenic mice
overexpressing IL-Ra in astrocytes, the threshold for seizure
generation increased.9
Therefore, the epileptogenic potential of IL-1b appears to be
independent of direct neurotoxicity.35–37 With respect to procon-
vulsive mechanisms, IL-1b can not only augment nitric oxide
formation to raise seizure susceptibility but can also increase
neuronal excitability by: directly inhibiting GABA(A) receptors,
increasing NMDA receptor function, and inhibiting K+ efﬂux.21,38–
41 The proconvulsive actions of IL-1b also depend on the activation
of sphingomyelinase and Src kinases in the hippocampus, which
can lead to the phosphorylation of NR2B subunit of the NMDA
receptor and evoke neuronal hyperexcitability.42
A minority of studies imply an anticonvulsant effect of IL-1b.
After synaptoneurosomes were incubated with IL-1b in a
concentration of 100 pg/ml, 1 ng/ml and 10 ng/ml in vitro, IL-1b
was shown to cause GABA-mediated increase in chloride
permeability,38 and intraperitoneal injection of 1mg IL-1b
increased the threshold for pentylenetetrazol-induced seizures
in mice.38 In addition, intraventricular injection of IL-1b (0.01, 0.1,
and 10 ng/300–350 g rat) exhibited signiﬁcant anticonvulsant
effects in an amygdala kindling model.12 In contrast to the
proconvulsive mechanisms of IL-1b, the potential anticonvulsive
pathways are far from being elucidated. One in vitro study found
that IL-1b could increase K+-evoked GABA release without
affecting K+-evoked glutamate release when the rise of intracellu-
lar Ca2+ concentration was prevented.41 This effect may result in a
preponderance of GABAergic over glutamatergic transmission. It
was also reported that intracellular Ca2+ concentration was
increased by IL-1b in a dose dependent fashion.43 Thus, the
extracellular concentration of IL-1b possibly has an impact on the
balance between glutamate andGABA release through its inﬂuence
on intracellular Ca2+ concentration. At relatively low levels, IL-1b
seems to exert an anticonvulsant effect by limiting intracellular
Ca2+ and enhancing GABAergic transmission, whereas higher
concentrations of IL-1b may have proconvulsive effects.2.2. Human studies
In genetic studies, homozygosity for the IL-1b-511 allele 2,
which is suggested to be an inducer of IL-1b, was overrepresented
in TLE patients with hippocampal sclerosis (HS) when compared to
both control subjects and TLE patients without HS.44,45 However,
other studies failed to demonstrate any signiﬁcant difference in
genotype and allele frequencies between TLE patients with HS and
controls.46–49 Likewise, an association between the frequency of
the IL-1b-511 allele 2 and an increased risk of febrile convulsions
has been reported,45,50 however, this association was refuted in
another study.51 The latter study only showed a trend towards an
increased frequency and carriage of the putative IL-1b-511 allele 2
ina sub-sampleof43patientswith febrile convulsionswhoreported
a positive family history of seizures in ﬁrst and/or second degree
relatives, but these trends did not reach statistical signiﬁcance. A
possible reason for these contradicting results is a different
prevalence of the allele in different ethnicities. Further studies with
larger patient populations in different ethnicities are required for
unveiling the association between IL-1b-511 allele 2 and epilepsy.
Several clinical studies adressed the change of IL-1b levels in
blood and cerebrospinal ﬂuid (CSF) of patients with focal epilepsy.
There were no signiﬁcant differences in the IL-1b concentration in
blood and CSF within 24 h after tonic–clonic seizures when
compared to control subjects.52 More recent studies in patients
with focal epilepsy similarly showed that postictal plasma
concentrations of IL-1b after complex partial or secondary
generalized tonic–clonic seizures did not signiﬁcantly differ from
baseline levels.53,54 However, the levels of IL-1Ra in serum can be
increased after a single complex partial or generalized tonic–clonic
seizure in patients with various focal epilepsy syndromes.4
Interictally, elevated IL-1b plasma concentration was seen in
patients with focal epilepsy due to benign cerebral tumors or
dysplasia.55 For patients with febrile seizures, there were no
signiﬁcant differences in postictal mean IL-1b levels in either CSF
or blood compared to controls,56 however, Virta et al. found that
the plasma IL-1Ra/IL-1 b ratio was the most signiﬁcant factor
connected to FS (OR, 41.5; 95% CI, 4.9–352.8) comparing with
plasma IL-1Ra, IL-1b, IL-6, IL-10 and TNFa.57
Unlike in blood and CSF, an increased expression of IL-1b and its
receptor in astrocytes,microglia, andneuronshas beendocumented
in brain specimens obtained frompatients surgically treated for TLE
with HS.58 IL-1b and its receptor were found to be highly expressed
in neurons and glia in patients with intractable epilepsy caused by
focal cortical dysplasia and glioneuronal tumors,3 whereas expres-
sion of IL-1b and its receptor in normal brain tissue were
negligible.3,58,59 Although the majority of studies demonstrates an
increased level of this cytokine in the epileptogenic zone, conclusive
evidence for a distinct role of IL-1b in epilepsy has yet to be shown.
2.3. Conclusion
Most animal and human studies have found an association
between the expression of IL-1b in the brain and seizures or
epilepsy. IL-1b plasma levels in patients with epilepsy are low and
postictal plasma concentrations of IL-1b after generalized tonic–
clonic or complex partial seizures did not signiﬁcantly differ from
baseline.52–54 Therefore, analyzing the blood of epilepsy patients in
clinical studies is not sufﬁcient to assess the function of IL-1b in the
pathogenesis of epilepsies. Animal models of epilepsy may be
necessary for a more detailed view. A large body of animal
experiments supports the epileptogenic potential of high IL-1b
concentrations, whereas the intraperitoneal and intraventricular
injection of relatively low doses of IL-1b seems to have anti-
epileptogenic effects.12,38 The inﬂuence of the extracellular concen-
tration of IL-1b on seizures or epilepsymerits further investigation.
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IL-6 is a multifunctional cytokine that regulates inﬂammatory
responses and other immune reactions.60,61 On target cells, its
signalsare transmittedthrough the IL-6 receptor complexconsisting
of IL-6 receptor (IL-6R) and two molecules of gp130.61–63 Both IL-6
and sIL-6R (the soluble form of IL-6R) can trigger gp130 signaling on
cells without membrane bound IL-6R.64,65
3.1. Animal studies
After seizures, IL-6 mRNA is rapidly induced in the hippocam-
pus, cortex, dentate gyrus, amygdala, and meninges, whereas up-
regulation of IL-6-receptor mRNA seems to be limited to the
hippocampus.11,66 In rodent models of limbic status epilepticus
(SE) induced by kainic acid, bicuculline methiodide, or electrical
stimulation, IL-6 mRNA and IL-6 protein were transiently
increased in glial cells, with maximal induction occurring 6 h
after SE.5 In another study of a rat SE model induced by lithium–
pilocarpine, the expression of IL-6mRNA peaked between 10 h and
16 h and returned to control levels within 5 days.66 Conversely, it
was at seven days after seizures that gp130 mRNA was up-
regulated in thalamus, cortex, amygdala, and hippocampus, which
showed a delayed reaction when compared to IL-6 mRNA.11 The
rapid increase of IL-6 expression may be associated with
membrane depolarization leading to accumulation of IL-6 mRNA
and IL-6 protein in neurons.67,68 This increase can be blocked by
lowering extracellular Ca2+ levels, blocking L-type Ca2+ channels,
or inhibiting Ca2+/calmodulin-dependent protein kinases.67
There have been conﬂicting reports on the inﬂuence of IL-6 on
seizures in recent years. In developing rats, intra-nasal adminis-
tration of IL-6 (50 or 500 ng) lengthened the latency and shortened
the duration of hyperthermia-induced seizures, which was
associated with activation of the adenosine receptor.69 On the
other hand, intranasal administration of IL-6 (400 ng) in adult rats
exacerbated the severity of seizures induced by pentylenetetra-
zole6 which was demonstrated by shorter latency to SE onset,
longer SE duration, and higher mortality. Ambiguous effects of IL-6
on seizure susceptibility were found not only in animals of
different developing states, but also in different transgenic animal
models. In IL-6 deﬁcient mice, aspartate levels signiﬁcantly
increased in the brain stem and hippocampus, which could be
responsible for the increased susceptibility to kainic-acid-induced
seizures.70 Moreover, neuronal injury was increased after kainic
acid induced seizures.70,71 These ﬁndings do not support the view
of neuroprotective and anticonvulsive properties of IL-6. However,
transgenic mice overexpressing IL-6 exhibit spontaneous tonic–
clonic seizures,72 which is possibly related to disrupted cholinergic
transmission of hippocampal cholinoceptive target neurons.8
Another study on transgenic mice overexpressing IL-6 in astro-
cytes reported an increased sensitivity to seizures induced by
glutamatergic agonists (i.e., kainic acid and NMDA) and a
constitutive loss of GABA- and parvalbumin-immunoreactive
neurons in the hippocampus.73 These results suggest that reduced
GABA-mediated inhibition is responsible for the propensity of
these rats to develop seizures.
What further confounds the ambiguous nature of IL-6 is that it
is necessary for normal development of the nervous system,74 but
an increased level of IL-6 in the brain has neurotoxic and
proconvulsive effects.6,72,73,75
3.2. Human studies
Studies have shown that IL-6 in plasma and CSF signiﬁcantly
increased within 24 h after generalized tonic-clonic seizures and
febrile seizures4,52,57,76, but was not changed after complex partialseizures in patients with chronic localization-related epilepsy,4
whereas IL-6 receptor plasma levels were slightly decreased or
remained unchanged.4
The increase of IL-6 levels in CSF after generalized tonic–clonic
seizures was found to be more pronounced than the increase in
plasma.52,77,78 Therefore, IL-6 synthesis was initially thought to
occur predominantly within the CNS. However, seizures them-
selves can activate the sympathetic nervous system (SNS) and
induce the release of catecholamines (CAs).79–83 Catecholamines
have been shown to mediate cytokine release from peripheral
blood mononuclear cells (PBMCs).84 Moreover, PBMCs from
epileptic patients showed greater production of IL-6 in response
to in vitro stimulation with mitogen as compared to controls.85
Thus, cytokine release from PBMCs would be another explanation
for the postictal increase of IL-6. Other studies suggest a
relationship between IL-6 plasma levels and different focal
epilepsies. IL-6 was found to be increased in TLE but not in
extra-TLE during the interictal stage.86 At 6 h after complex partial
or secondary generalized tonic–clonic seizures in patientswith TLE
or extratemporal epilepsies, only the TLE group showed a
signiﬁcant rise in plasma levels of IL-6.53 Previous results from
our group showed a rapid increase of IL-6 plasma levels after
seizures in patients with TLE without hippocampal sclerosis (HS),
whereas this increase was lacking in patients with HS.54 These
ﬁndings suggest a possible neuroprotective effect of IL-6 in TLE,
which helps to prevent the development of HS, assuming the
systemic IL-6 increase reﬂects similar changes in the mesial
temporal region. However, activation of SNS by temporal lobe
structures, e.g. hippocampus, and consecutive release of CAs and
raise of IL-6 plasma levels cannot be ruled out. In conclusion, the IL-
6 level in plasma does not reliably reﬂect its brain level.
3.3. Conclusion
Animal experiments show that a high concentrationof IL-6 in the
brain is an obvious neurotoxic and proconvulsive factor, especially
for the adult brain, although IL-6 is necessary for the normal CNS
development. The increased expression of IL-6 both in brain and
blood is closely associated with seizures and epilepsy. However, it
remains unclear whether elevated blood levels of IL-6 allow a
conclusion to be drawn about the expression and function of IL-6 in
epileptogenic brain areas. In vivo studies on IL-6 expression in the
human brain are difﬁcult to perform for the obvious reason of
limited access to brain tissue from the epiletogenic zone. Animal
models that closely resemble certain epilepsy syndromes and allow
a fractionated analysis of epiletogenesis are required.
4. TNFa
In the CNS, TNFa can activate its two receptors (p55 and p75)
and may modulate cell-signaling pathways.87,88 The p55 receptor
has been implicated in the activation of programmed cell death,
whereas p75 receptors are associated with activation of the
nuclear factor Kappa B (NF-kB) system.89–91
4.1. Animal studies
After seizures evoked by amygdala kindling in rats, TNFamRNA
levels showed a signiﬁcant up-regulation in the parietal, prefron-
tal, and piriform cortex, as well as in the amygdala and
hippocampus,2,92 which returned to baseline within 3 weeks.2
Limbic SE in rodents also rapidly and transiently enhanced TNFa
mRNA in the hippocampus with a peak effect at 6 h.5
TNFa plays a dichotomous role in epilepsy. Intrahippocampal
injection of murine-recombinant TNFa (2.5 and 15.0 pmol/25 g
mouse) potently inhibited seizures in mice.7 Transgenic mice with
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whereasmice lacking TNFa receptors showed prolonged seizures.7
In contrast, transgenic mice expressing TNFa in neurons through-
out the brain developed seizures and died prematurely.93
Intraperitoneal injection of TNFa (5.0 mg/kg) prolonged the
duration of epileptiform discharges in amygdala-kindled rats.94
In a computational model of neuron-glia interaction in TNFa-
mediated synaptic scaling, TNFa overexpression by glia induced
seizure-like activity suggested that TNFa diffusion may be
responsible for epileptogenesis after localized brain lesions.95
The pro- and anti-convulsive effects of TNFa may be derived
from activation of its different receptors in the brain, p55 and p75.
Balosso et al. found that the anticonvulsant activity of TNFa in
mice was mediated by the neuronal p75 receptor.7 In the same
study, p75 receptor knockout mice displayed enhanced seizure
activity, whereas p55 receptor knockout mice had reduced seizure
susceptibility.7 In another report, TNFa changed the molecular
stoichiometry of synaptic AMPA receptors and increased excitato-
ry synaptic activity through interactions with p55 receptors.96 P55
signaling through apoptosis signal-regulating kinase 1 might be a
key event in the death of neurons following seizures.97 These
ﬁndings suggest that the p55 pathway is involved in proconvulsive
and neurotoxic effects of TNFa in animal models of epilepsy and
that the p75 pathway is associated with anticonvulsive effects.
However, the mechanisms responsible for the preponderance of
the p55 pathway over the p75 pathway or vice versa are still
unclear.
Several studies indicate that TNFa possibly acts in a concen-
tration-dependent manner. TNFa has been shown to play a
proconvulsive role in Shigella-mediated seizures at low concen-
trations, but exerted an anticonvulsive effect at higher concentra-
tions.98 In addition, it was also reported that picomolar in vitro
concentrations of TNFa could efﬁciently trigger the p55 pathway,
whereas activation of p75 required signiﬁcantly higher concen-
trations.99 Therefore, low concentrations of TNFa may predomi-
nantly activate proconvulsive effects via p55 while high
concentrations of TNFa can play an anticonvulsive role through
the p75 pathway.
4.2. Human studies
There are little data on TNFa in patients with epilepsy. No
signiﬁcant changes of TNFa have been found in plasma or CSF in
patients within 24 h after acute tonic–clonic seizures or partial
secondarily generalized seizures.52,54 There were also no signiﬁ-
cant changes of TNFa in plasma or CSF of patients with febrile
seizures.57,100 Studies on the intracerebral expression of TNFa in
these patients are lacking.
4.3. Conclusion
In animal models, seizures can induce the expression of TNFa
mRNA in brain although its mechanism and relevance remain
elusive. Animal studies have clearly demonstrated that TNFa plays
a dichotomous role in seizures depending on the activation of
different downstream receptors, which possibly is related to its
extracellular concentration. However, due to absence of clinical
studies, these conclusions have not yet been veriﬁed in humans.
5. Other cytokines
5.1. IL-2
IL-2 plays an important role in regulating the immune response,
particularly through T-cell activation.101,102 Intraventricular ad-
ministration of IL-2 in DBA/2 mice promotes seizure generation invarious models of experimental epilepsy, including sound- and
chemoconvulsant-induced seizures.103 However, IL-2 levels in
plasma and CSF remained unchanged in patients with prolonged
febrile seizures, with or without encephalopathy, during the acute
stage.104
5.2. IL-10
IL-10 has broad anti-inﬂammatory properties by its inhibition
of antigen-presenting cell function and the suppression of
production of proinﬂammatory cytokines and chemokines.105,106
There were no differences in plasma IL-10 between patients with
FS and controls.57 Several animal studies and clinical observations
suggest an anticonvulsant effects of IL-10. One report showed
protective effects of IL-10 against the development of epileptiform
activity evoked by transient episodes of hypoxia in rat hippocam-
pal slices.107 In hyperthermia-induced seizures of immature rats,
the seizure threshold temperature in IL-10 treated rats was
signiﬁcantly higher than in the saline treated controls.108
Furthermore, the frequencies of the IL-10 592C allele and
1082A/-819C/-592C haplotype, which have been reportedly
associated with increased production of IL-10,109 were signiﬁcant-
ly lower in patients suffering from FS as compared to healthy
controls.108
5.3. Fibroblast growth factor (FGF)
FGF-1 and FGF-2 are members of the FGF family that regulate
cell proliferation, migration, differentiation, and survival.110,111
After a single episode of amygdala kindling, FGF-2 mRNA levels
were increased in hippocampus, neocortex, and hypothalamus.112
In chronic electroconvulsive shock treated rats, signiﬁcantly
elevated FGF-2 was found in the frontal and rhinal cortex, which
postictally peaked at 20 h and remained signiﬁcantly elevated for
up to 72 h.113 However, the role of FGF-2 in epileptogenesis is
contested with various studies suggesting conﬂicting roles. Fetal
hippocampal CA3 cell grafts enriched with FGF-2 and brain-
derived neurotrophic factor (BDNF) suppressed aberrant mossy
ﬁber sprouting in the injured middle-aged hippocampus.114
Moreover, supplementation of FGF-2 and BDNF in the hippocam-
pus lesioned by prolonged seizures limited damage and reduced
spontaneous seizures.115 However, transgenicmice with increased
FGF-2 expression displayed increased susceptibility to kainate-
induced seizures, but reduced neuronal death.116 Other studies
found that FGF-2 was able to alter the electrical activity of
hippocampal neurons and to cause seizures117 while intraperito-
neal injection of FGF-1 in kainic acid treated rats signiﬁcantly
decreased tonic-clonic convulsions and mortality.118 Taken
together, these results indicate that FGF-2 is implicated in both
seizure-induced plasticity and seizure susceptibility in animal
models.
There are very few clinical studies on FGF in human epilepsy. In
one group of corticectomy specimens from epileptic patients,
including focal cortical dysplasia, tubers of tuberous sclerosis, and
gliotic lesions, FGF-2 expression was observed in abnormal
neuroglial cells, including balloon cells and dysplastic neurons,
and reactive astrocytes.119
5.4. IL-3, IL-8, LIF and interferon-g
Intraventricular administration of high doses of hr-IL-3 in rats
produced 3–5 Hz spike-wave complexes that were associated with
episodes of arrest.120 IL-8 concentration in serum and CSF of
patients with refractory epilepsy was signiﬁcantly increased after
seizures, including focal, generalized tonic–clonic, myoclonic,
atypical absence, and typical absence seizures.78 After seizures
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to be up-regulated in the hippocampus, neocortex, dentate gyrus,
and meninges;11,66 LIF receptor mRNA was induced in the
hippocampus and neocortex.11,66 Interferon-g was associated
with the development of limbic seizures inWest Nile virus infected
mice and absence of interferon-g during the development of the
CNS may cause intracerebral alterations resulting in enhanced
tolerance to epileptic stimuli.121
5.5. Conclusion
Generally, limited information is available on the expression
and function of cytokines, apart from IL-1b, IL-6 and TNFa, in
seizure and epilepsy. However, the experimental data suggest a
postictal activation of cytokine networks rather than the release of
single cytokines. In particular, the anticonvulsive role of IL-10 and
the proconvulsive role of FGF-2 appear to merit further studies.
6. Inﬂuence of cytokines on blood–brain-barrier (BBB)
permeability in epilepsy
In human and animal studies of epilepsy, BBB failure has been
shown before, during, and after seizures. The underlying mechan-
isms for this effect are thought to be complex and have yet to be
elucidated in detail.122–126 On one hand, the etiology of epilepsy,
e.g. stroke, traumatic brain injury, or central nervous system
infections, may result in compromised BBB function.127–130 On the
other hand, epileptic seizures by themselves cause transient
changes in the functional and structural properties of the
BBB.124,131 Additionally, the intrinsic inﬂammation induced by
seizures may also lead to enhanced BBB permeability.
Disruption of BBB permeability is a possible pathway for
cytokines inﬂuencing seizures and epilepsy. Several studies
revealed BBB ‘failure’ after administration of IL-1, IL-6, TNFa,
and interferon-g.132–134 A recent study reported that intravenous
administration of IL-1Ra exhibited signiﬁcant reduction of SE
intensity and BBB damage in the rat.135 Of note, in a mouse model
of epilepsy induced by pilocarpine, Fabene et al., found that
leukocyte–endothelial interactions were altered by seizures and
played an important role in BBB damage and seizure generation.136
The exact role of altered BBB permeability in the development and
course of epilepsy is not well deﬁned. However, a series of studies
have supported the views that transient openings of the BBB
facilitate both behavioral and electrographic seizures and may
establish a link between the systemic immune system and the
epileptogenic zone.135–137
7. Conclusion
A growing body of evidence suggests that there is an array of
cytokines involved in epilepsy. These substances are activated by
seizures, but their precise role in epilepsy is not yet clear. Most
studies have been focused on three cytokines: IL-1b, IL-6 and
TNFa. Levels of these substances increase quickly after either
generalized tonic–clonic or complex partial seizures and return to
baseline after varying time intervals. Seizures not only induce the
expression of cytokines in the brain but also change peripheral
cytokine levels. In recent years, the vagus nerve has been found to
play an important role in signaling the immune status to the brain
or vice versa.138,139 Changes in peripheral cytokine levels, such as
IL-6 and IL-8, were reported after vagus nerve stimulation in
patients with refractory epilepsy.140–142 Therefore, future studies
are warranted to characterize the impact of the vagus nerve on the
relationship between seizures and peripheral cytokines.
Available studies highlight the dichotomous role of IL-1b, IL-6
and TNFa in epileptogenesis. These molecules have demonstratedpro- and anticonvulsive properties in different animal studies. The
difﬁculty to extrapolate the results of these studies to human
epilepsies remains. This is because studies in epileptic patients are
often limited to cytokine detection in blood or CSF, and only few
reports study brain specimens obtained from surgical candidates
or autopsies. There is a great need for further studies regarding the
role(s) of cytokines in human epilepsy. A key point to be addressed
in further studies is whether, and to what extent, endogeneous
cytokine release is relevant for the process of epileptogenesis and if
this process can be prevented by immunomodulatory treatment.
References
1. World Health Organisation (WHO) Atlas: epilepsy care in the world WHO
Geneva; 2005.
2. Plata-Salama´n CR, Ilyin SE, Turrin NP, Gayle D, Flynn MC, Romanovitch AE,
et al. Kindling modulates the IL-1beta system, TNFalpha, TGF-beta1 and
neuropeptide mRNAs in speciﬁc brain regions. Brain Res Mol Brain Res
2000;75:248–58.
3. Ravizza T, Vezzani A. Status epilepticus induces time-dependent neuronal and
estrocytic expression of IL-1 receptor type-I in the rat limbic system. Neuro-
science 2006;137:301–8.
4. Lehtima¨ki KA, Kera¨nen T, Palmio J, Ma¨kinen R, Hurme M, Honkaniemi J, et al.
Increased plasma levels of cytokines after seizures in localization-related
epilepsy. Acta Neurol Scand 2007;116:226–30.
5. Vezzani A, Moneta D, Richichi C, Aliprandi M, Burrows SJ, Ravizza T, et al.
Functional role of inﬂammatory cytokines and antiinﬂammatory molecules in
seizures and epileptogenesis. Epilepsia 2002;43:30–5.
6. Kalueff AV, Lehtimaki KA, Ylinen A, Honkaniem J, Peltola J. Intranasal admin-
istration of human IL-6 increases the severity of chemically induced seizures in
rats. Neurosci Lett 2004;365:106–10.
7. Balosso S, Ravizza T, Perego C, Peschon J, Campbell IL, De Simoni MG, et al.
Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann
Neurol 2005;57:804–12.
8. Steffensen SC, Campbell IL, Henriksen SJ. Site-speciﬁc hippocampal patho-
physiology due to cerebral overexpression of interleukin-6 in transgenic mice.
Brain Res 1994;652:149–53.
9. Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, et al. Powerful
anticonvulsant action of IL-1 receptor antagonist on intracerebral injection
and astrocytic overexpression in mice. Proc Natl Acad Sci USA 2000;97:11534–
9.
10. Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources,
receptors, effects, and inducers. Clin Microbiol Rev 1997;10:742–80.
11. Lehtima¨ki KA, Peltola J, Koskikallio E, Kera¨nen T, Honkaniemi J. Expression of
cytokines and cytokine receptors in the rat brain after kainic acid-induced
seizures. Mol Brain Res 2003;110:253–60.
12. Sayyah M, Beheshti S, Shokrgozar MA, Eslami-far A, Deljoo Z, Khabiri AR, et al.
Antiepileptogenic and anticonvulsant activity of interleukin-1 beta in amyg-
dala-kindled rats. Exp Neurol 2005;191:145–53.
13. Dube´ C, Vezzani A, Behrens M, Bartfai T, Baram TZ. Interleukin-1b contributes
to the generation of experimental febrile seizures. Ann Neurol 2005;57:152–5.
14. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1)
receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1
signal transduction. J Biol Chem 1991;266:10331–6.
15. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J
1994;8:1314–25.
16. GlaccumMB, Stocking KL, Charrier K, Smith JL, Willis CR, Maliszewski C, et al.
Phenotypic and functional characterization of mice that lack the type I
receptor for IL-1. J Immunol 1997;159:3364–71.
17. Horai R, AsanoM, Sudo K, KanukaH, SuzukiM, NishiharaM, et al. Production of
mice deﬁcient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and
IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced
fever development and glucocorticoid secretion. J Exp Med 1998;187:1463–75.
18. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, et al.
Inﬂammatory cytokines and related genes are induced in the rat hippocampus
by limbic status epilepticus. Eur J Neurosci 2000;12:2623–33.
19. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM. The relationship of
interleukin-1 and immune function to sleep in humans. Psychosom Med
1986;48:309–18.
20. Min KJ, Jou I, Joe E. Plasminogen-induced IL-1beta and TNFalpha production in
microglia is regulated by reactive oxygen species. Biochem Biophys Res Com-
mun 2003;312:969–74.
21. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, et al.
Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium
increase through activation of the Src family of kinases. J Neurosci
2003;23:8692–700.
22. Wisse BE, Ogimoto K, Schwartz MW. Role of hypothalamic interleukin-1beta
(IL-1beta) in regulation of energy homeostasis by melanocortins. Peptides
2006;27:265–73.
23. Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M. Convulsants
induce interleukin-1 beta messenger RNA in rat brain. Biochem Biophys Res
Commun 1990;171:832–7.
G. Li et al. / Seizure 20 (2011) 249–25625424. Donnelly S, Loscher C, Mills KH, Lynch MA. Glycerol-induced seizure: involve-
ment of IL-1beta and glutamate. Neuroreport 1999;10:1821–5.
25. Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, et al.
Interleukin-1beta immunoreactivity and microglia are enhanced in the rat
hippocampus by focal kainate application: functional evidence for enhance-
ment of electrographic seizures. J Neurosci 1999;19:5054–65.
26. Eriksson C, Tehranian R, Iverfeldt K, Winblad B, Schultzberg M. Increased
expression of mRNA encoding interleukin-1beta and caspase-1, and the
secreted isoform of interleukin-1 receptor antagonist in the rat brain following
systemic kainic acid administration. J Neurosci Res 2000;60:266–79.
27. Svensson I, Waara L, Johansson L, Bucht A, Cassel G. Soman-induced interleu-
kin-1 beta mRNA and protein in rat brain. Neurotoxicology 2001;2:355–62.
28. Okada K, Matsunaga K, Yuhi T, Kuroda E, Yamashita U, Tsuji S. The longterm
high-frequency repetitive transcranial magnetic stimulation does not induce
mRNA expression of inﬂammatory mediators in the rat central nervous
system. Brain Res 2002;57:37–41.
29. Williams J, Berti R, Yao C, Price RA, Velarde LC, Koplovitz I, et al. Central neuro-
inﬂammatory gene response following soman exposure in the rat. Neurosci
Lett 2003;349:147–50.
30. Chapman S, Kadar T, Gilat E. Seizure duration following sarin exposure affects
neuro-inﬂammatorymarkers in the rat brain.Neurotoxicology 2006;27:277–83.
31. Dhote F, Peinnequin A, Carpentier P, Baille V, Delacour C, Foquin A, et al.
Prolonged inﬂammatory gene response following somaninduced seizures in
mice. Toxicology 2007;238:166–76.
32. RizziM,PeregoC,AliprandiM,RichichiC,RavizzaT,ColellaD,etal.Gliaactivation
and cytokine increase in rat hippocampus by kainic acid-induced status
epilepticus during postnatal development. Neurobiol Dis 2003;14:494–503.
33. Oprica M, Spulber SD, Aronsson AF, Post C, Winblad B, Schultzberg M. The
inﬂuence of kainic acid on core temperature and cytokine levels in the brain.
Cytokine 2006;35:77–87.
34. Donnelly S, Loscher CE, Lynch MA, Mills KH. Whole-cell but not acellular
pertussis vaccines induce convulsive activity in mice: evidence of a role for
toxin-induced interleukin-1beta in a new murine model for analysis of
neuronal side effects of vaccination. Infect Immun 2001;69:4217–23.
35. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic
and excitotoxic neuronal damage in the rat. Brain Res Bull 1992;9:243–6.
36. Ma XC, Gottschall PE, Chen LT, Wiranowska M, Phelps CP. Role and mechan-
isms of interleukin-1 in the modulation of neurotoxicity. Neuroimmunomo-
dulation 2002–2003;10:199–207.
37. Hailer NP, Vogt C, Korf HW, Dehghani F. Interleukin-1beta exacerbates and
interleukin-1 receptor antagonist attenuates neuronal injury and microglial
activation after excitotoxic damage in organotypic hippocampal slice cultures.
Eur J Neurosci 2005;21:2347–60.
38. Miller LG, Galpern WR, Dunlap K, Dinarello CA, Turner TJ. Interleukin-1
augments gamma-aminobutyric acidA receptor function in brain. Mol Phar-
macol 1991;39:105–8.
39. Wang S, Cheng Q, Malik S, Yang J. Interleukin-1beta inhibits gamma-amino-
butyric acid type A (GABA(A)) receptor current in cultured hippocampal
neurons. J Pharmacol Exp Ther 2000;292:497–504.
40. Meini A, Benocci A, Frosini M, Sgaragli G, Pessina G, Aldinucci C, et al. Nitric
oxide modulation of interleukin-1[beta]-evoked intracellular Ca2+ release in
human astrocytoma U-373 MG cells and brain striatal slices. J Neurosci
2000;20:8980–6.
41. Zhu G, Okada M, Yoshida S, Mori F, Ueno S, Wakabayashi K, et al. Effects of
interleukin-1beta on hippocampal glutamate and GABA releases associated
with Ca2+-induced Ca2+ releasing systems. Epilepsy Res 2006;71:107–16.
42. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, et al. A
novel non-transcriptional pathway mediates the proconvulsive effects of
interleukin-1beta. Brain 2008;131:3256–65.
43. Pita I, Jelaso AM, Ide CF. IL-1beta increases intracellular calcium through an IL-
1 type 1 receptor mediatedmechanism in C6 astrocytic cells. Int J Dev Neurosci
1999;17:813–20.
44. Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M. Interleukin
(IL)-1 beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in
patients with temporal lobe epilepsy. Ann Neurol 2000;47:571–4.
45. Kanemoto K, Kawasaki J, Yuasa S, Kumaki T, Tomohiro O, Kaji R, et al. Increased
frequency of interleukin-1beta-511T allele in patients with temporal lobe
epilepsy, hippocampal sclerosis, and prolonged febrile convulsion. Epilepsia
2003;44:796–9.
46. Heils A, Haug K, Kunz WS, Fernandez G, Horvath S, Rebstock J, et al. Interleu-
kin-1 beta polymorphism and susceptibility to temporal lobe epilepsy with
hippocampal sclerosis. Ann Neurol 2000;48:948–50.
47. Buono RJ, Ferraro TN, O’Connor MJ, Sperling M, Ryan S, Scattergood T, et al.
Lack of association between an interleukin 1 beta (IL-1b) gene variation and
refractory temporal lobe epilepsy. Epilepsia 2001;42:782–4.
48. Jin L, Jia Y, Zhang B, Xu Q, Fan Y, Wu LW, et al. Association analysis of a
polymorphism of interleukin 1b (IL-1b) gene with temporal lobe epilepsy in a
Chinese population. Epilepsia 2003;44:1306–9.
49. Ozkara C, Uzan M, Tanriverdi T, Baykara O, Ekinci B, Yeni N, et al. Lack of
association between IL-1beta/alpha gene polymorphisms and temporal lobe
epilepsy with hippocampal sclerosis. Seizure 2006;15:288–91.
50. Virta M, Hurme M, Helminen M. Increased frequency of interleukin-1beta
(-511) allele 2 in febrile seizures. Pediatr Neurol 2002;26:192–5.
51. Tilgen N, Pfeiffer H, Cobilanschi J, Rau B, Horvath S, Elger CE, et al. Association
analysis between the human interleukin 1beta (-511) gene polymorphism and
susceptibility to febrile convulsions. Neurosci Lett 2002;334:68–70.52. Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, et al.
Interleukin-6 and Interleukin-1 receptor antagonist in cerebrospinal ﬂuid
from patients with recent tonic-clonic seizures. Epilepsy Res 2000;41:205–11.
53. Alapirtti T, Rinta S, Hulkkonen J, Ma¨kinen R, Kera¨nen T, Peltola J. Interleukin-6,
interleukin-1 receptor antagonist and interleukin-1beta production in
patients with focal epilepsy: a video-EEG study. J Neurol Sci 2009;280:94–7.
54. Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Ko¨ller M, Lorenz R, et al.
Etiology and site of temporal lobe epilepsy inﬂuence postictal cytokine
release. Epilepsy Res 2009;86:82–8.
55. Nowak M, Bauer S, Cepok S, Todorova-Rudolph A, Li G, Tackenberg B, et al.
Interictal imunological changes in patients with refractory epilepsy. Epilepsia
2009;50(3):044.
56. Lahat E, Livne M, Barr J, Katz Y. Interleukin-1b levels in serum and cerebro-
spinal ﬂuid of children with febrile seizures. Pediatr Neurol 1997;17:34–6.
57. Virta M, Hurme M, Helminen M. Increased plasma levels of pro- and anti-
inﬂammatory cytokines in patients with febrile seizures. Epilepsia
2002;43:920–3.
58. Ravizza T, Gagliardi B, Noe´ F, Boer K, Aronica E, Vezzani A. Innate and adaptive
immunity during epileptogenesis and spontaneous seizures: evidence from
experimental models and human temporal lobe epilepsy. Neurobiol Dis
2008;29:142–60.
59. Giometto B, Bozza F, Faresin F, Alessio L, Mingrino S, Tavolato B. Immune
inﬁltrates and cytokines in gliomas. Acta Neurochir (Wien) 1996;138:50–6.
60. Hirano T, Taga T, Yamasaki K, Matsuda T, Tang B, Muraguchi A, et al. A
multifunctional cytokine (IL-6/BSF-2) and its receptor. Int Arch Allergy Appl
Immunol 1989;88:29–33.
61. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and
gp130. Blood 1995;86:1243–54.
62. HibiM,MurakamiM, SaitoM, Hirano T, Taga T, Kishimoto T.Molecular cloning
and expression of an IL-6 signal transducer, gp130. Cell 1990;63:1149–57.
63. Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T. Molecular cloning of a murine
IL-6 receptor-associated signal transducer, gp130, and its regulated expres-
sion in vivo. J Immunol 1992;148:4066–71.
64. Yasukawa K, Futatsugi K, Saito T, Yawata H, Narazaki M, Suzuki H, et al.
Association of recombinant soluble IL-6-signal transducer, gp130, with a
complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA
for soluble gp130. Immunol Lett 1992;31:123–30.
65. Mu¨ller-Newen G, Ku¨ster A, Hemmann U, Keul R, Horsten U, Martens A, et al.
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on
IL-6 responses. J Immunol 1998;161:6347–55.
66. Rosell DR, Nacher J, Akama KT, McEwen BS. Spatiotemporal distribution of
gp130 cytokines and their receptors after status epilepticus: comparison with
neuronal degeneration andmicroglial activation.Neuroscience 2003;122:329–
48.
67. Sallmann S, Ju¨ttler E, Prinz S, Petersen N, Knopf U, Weiser T, et al. Induction of
Interleukin-6 by depolarization of neurons. J Neurosci 2000;20:8637–42.
68. Suzuki S, Tanaka K, Nogawa S, Dembo T, Kosakai A, Fukuuchi Y. Expression of
interleukin-6 is suppressed by inhibition of voltage-sensitive Na+/Ca2+ chan-
nels after cerebral ischemia. Neuroreport 2000;11:2565–9.
69. Fukuda M, Morimoto T, Suzuki Y, Shinonaga C, Ishida Y. Interleukin-6 attenu-
ates hyperthermia-induced seizures in developing rats. Brain Dev
2007;29:644–8.
70. PenkowaM,Molinero A, Carrasco J, Hidalgo J. Interleukin-6 deﬁciency reduces
the brain inﬂammatory response and increases oxidative stress and neuro-
degeneration after kainic acid-induced seizures. Neuroscience 2001;102:805–
18.
71. De Luca G, Di Giorgio RM, Macaione S, Calpona PR, Costantino S, Di Paola ED,
et al. Susceptibility to audiogenic seizure and neurotransmitter amino acid
levels in different brain areas of IL-6-deﬁcient mice. Pharmacol Biochem Behav
2004;78:75–81.
72. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al.
Neurologic disease induced in transgenic mice by cerebral overexpression of
interleukin 6. Proc Natl Acad Sci USA 1993;90:10061–5.
73. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL.
Profound increase in sensitivity to glutamatergic but not cholinergic agonis-
tinduced seizures in transgenic mice with astrocyte production of IL-6. J
Neurosci Res 2003;73:176–87.
74. Nakashima K, Taga T. Mechanisms underlying cytokine-mediated cell-fate
regulation in the nervous system. Mol Neurobiol 2002;25:233–44.
75. Jonakait GM. The effects of maternal inﬂammation on neuronal development:
possible mechanismsInt. J Dev Neurosci 2007;25:415–25.
76. Peltola J, Laaksonen J, Haapala AM, Hurme M, Rainesalo S, Keranen T. Indi-
cators of inﬂammation after recent tonic–clonic epileptic seizures correlate
with plasma interleukin-6 levels. Seizure 2002;11:44–6.
77. Peltola J, Hurme M, Miettinen A, Kera¨nen T. Elevated levels of interleukin-6
may occur in cerebrospinal ﬂuid from patients with recent epileptic seizures.
Epilepsy Res 1998;31:129–33.
78. Billiau AD, Witters P, Ceulemans B, Kasran A, Wouters C, Lagae L. Intravenous
immunoglobulins in refractory childhood-onset epilepsy: effects on seizure
frequency, EEG activity, and cerebrospinal ﬂuid cytokine proﬁle. Epilepsia
2007;48:1739–49.
79. Rosenbaum KJ, Sapthavichaikul S, Skovsted P. Sympathetic nervous system
response to lidocaine induced seizures in cats. Acta Anaesthesiol Scand
1978;22:548–55.
80. Simon RP, Aminoff MJ, Benowitz NL. Changes in plasma catecholamines after
tonic–clonic seizures. Neurology 1984;34:255–7.
G. Li et al. / Seizure 20 (2011) 249–256 25581. Mann JJ, Manevitz AZ, Chen JS, Johnson KS, Adelsheimer EF, Azima-Heller R,
et al. Acute effects of single and repeated electroconvulsive therapy on plasma
catecholamines and blood pressure in major depressive disorder. Psychiatry
Res 1990;34:127–37.
82. Sakamoto K, Saito T, Orman R, Koizumi K, Lazar J, Salciccioli L, et al.Autonomic
consequences of kainic acid-induced limbic cortical seizures in rats: periph-
eral autonomic nerve activity, acute cardiovascular changes, and death. Epi-
lepsia 2008;49:982–96.
83. Bauer S, Ko¨ller M, Cepok S, Todorova-Rudolph A, NowakM, NockherWA, et al.
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy.
Exp Neurol 2008;211:370–7.
84. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system
injury-induced immune deﬁciency syndrome. Nat Rev Neurosci 2005;6:775–
86.
85. Paciﬁci R, Paris L, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Cytokine production
in blood mononuclear cells from epileptic patients. Epilepsia 1995;36:384–7.
86. Liimatainen S, Fallah M, Kharazmi E, Peltola M, Peltola J. Interleukin-6 levels
are increased in temporal lobe epilepsy but not in extra-temporal lobe
epilepsy. J Neurol 2009;256:796–802.
87. Loetscher H, Steinmetz M, Lesslauer W. Tumor necrosis factor: receptors and
inhibitors. Cancer Cells 1991;3:221–6.
88. Mukai Y, ShibataH, Nakamura T, Yoshioka Y, Abe Y, Nomura T, et al. Structure–
function relationship of tumor necrosis factor (TNF) and its receptor interac-
tion based on 3D structural analysis of a fully active TNFR1-selective TNF
mutant. J Mol Biol 2009;385:1221–9.
89. Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M. Tumor necrosis
factor (TNF) receptor 1 signaling downstream of TNF receptor-associated
factor 2 Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for
activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal
kinase/stress-activated protein kinase. J Biol Chem 1997;272:26079–82.
90. Zhuang L, Wang B, Shinder GA, Shivji GM, Mak TW, Sauder DN. TNF receptor
p55 plays a pivotal role in murine keratinocyte apoptosis induced by ultravi-
olet B irradiation. J Immunol 1999;162:1440–7.
91. Sheng WS, Hu S, Ni HT, Rowen TN, Lokensgard JR, Peterson PK. TNFalpha-
induced chemokine production and apoptosis in humanneural precursor cells.
J Leukoc Biol 2005;78:1233–41.
92. Godlevsky LS, Shandra AA, Oleinik AA, Vastyanov RS, Kostyushov VV, Tim-
chishin OL. TNFalpha in cerebral cortex and cerebellum is affected by amyg-
dalar kindling but not by stimulation of cerebellum. Pol J Pharmacol
2002;54:655–60.
93. Probert L, Akassoglou K, PasparakisM, Kontogeorgos G, Kollias G. Spontaneous
inﬂammatory demyelinating disease in transgenic mice showing central
nervous system-speciﬁc expression of tumor necrosis factor alpha. Proc Natl
Acad Sci USA 1995;92:11294–8.
94. Shandra AA, Godlevsky LS, Vastyanov RS, Oleinik AA, Konovalnko VL, Rapoport
EN, et al. The role of TNFalpha in amygdala kindeled rats. Neurosci Res
2002;42:147–53.
95. Savin C, Triesch J, Meyer-Hermann M. Epileptogenesis due to glia-mediated
synaptic scaling. J R Soc Interface 2009;6:655–68.
96. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA
receptor and GABA receptor trafﬁcking by tumor necrosis factor-alpha. J
Neurosci 2005;25:3219–28.
97. Shinoda S, Skradski SL, Araki T, Schindler CK, Meller R, Lan JQ, et al. Formation
of a tumour necrosis factor receptor 1 molecular scaffolding complex and
activation of apoptosis signal-regulating kinase 1 during seizure-induced
neuronal death. Eur J Neurosci 2003;17:2065–76.
98. Yuhas Y, Weizman A, Ashkenazi S. Bidirectional concentration-dependent
effects of tumor necrosis factor alpha in Shigella dysenteriae-related seizures.
Inf Immun 2003;71:2288–91.
99. Grell M,Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a)
is the high-afﬁnity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci
USA 1998;95:570–5.
100. Haspolat S, Mihci E, Coskun M, Gu¨mu¨slu¨ S, Ozben T, Yeg˘in O. Interleukin-
1beta, tumor necrosis factor-alpha, and nitrite levels in febrile seizures. J Child
Neurol 2002;17:749–51.
101. Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and
proliferation signaling pathways in T lymphocytes. Immunol Invest 2004;
33:109–42.
102. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol 2004;172:3983–8.
103. De Sarro G, Rotiroti D, AudinoMG, Gratteri S, Nistico´ G. Effects of interleukin-2
on various models of experimental epilepsy in DBA/2 mice. Neuroimmuno-
modulation 1994;1:361–9.
104. Ichiyama T, Suenaga N, Kajimoto M, Tohyama J, Isumi H, Kubota M, et al.
Serum and CSF levels of cytokines in acute encephalopathy following pro-
longed febrile seizures. Brain Dev 2008;30:47–52.
105. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment
of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:629–39.
106. O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-
10 or its antagonists in human disease. Immunol Rev 2008;223:114–31.
107. Levin SG, Godukhin OV. Protective effects of interleukin-10 on the develop-
ment of epileptiform activity evoked by transient episodes of hypoxia in rat
hippocampal slices. Neurosci Behav Physiol 2007;37:467–70.
108. Ishizaki Y, Kira R, FukudaM, Torisu H, Sakai Y, Sanefuji M, et al. Interleukin-10
is associated with resistance to febrile seizures: genetic association and
experimental animal studies. Epilepsia 2009;50:761–7.109. Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE, Huizinga TW. Transcrip-
tion of the IL10 gene reveals allele-speciﬁc regulation at the mRNA level. Hum
Mol Genet 2004;13:1755–62.
110. GoldfarbM. Functions of ﬁbroblast growth factors in vertebrate development.
Cytokine Growth Factor Rev 1996;7:311–25.
111. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential
for development. Bioessays 2000;22:108–12.
112. Simonato M, Molteni R, Bregola G, Muzzolini A, Piffanelli M, Beani L, et al.
Different patterns of induction of FGF-2, FGF-1 and BDNF mRNAs
during kindling epileptogenesis in the rat. Eur J Neurosci 1998;10:
955–63.
113. Gwinn RP, Kondratyev A, Gale K. Time-dependent increase in basic ﬁbroblast
growth factor protein in limbic regions following electroshock seizures.
Neuroscience 2002;114:403–9.
114. Rao MS, Hattiangady B, Shetty AK. Fetal hippocampal CA3 cell grafts enriched
with FGF-2 and BDNF exhibit robust long-term survival and integration and
suppress aberrant mossy ﬁber sprouting in the injured middle-aged hippo-
campus. Neurobiol Dis 2006;21:276–90.
115. Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, et al. Localized
delivery of ﬁbroblast growth factor-2 and brain-derived neurotrophic factor
reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA
2009;106:7191–6.
116. Zucchini S, Buzzi A, Barbieri M, Rodi D, Paradiso B, Binaschi A, et al. Fgf-2
overexpression increases excitability and seizure susceptibility but decreases
seizure-induced cell loss. J Neurosci 2008;28:13112–24.
117. Liu Z, Holmes GL. Basic ﬁbroblast growth factor-induced seizures in rats.
Neurosci Lett 1997;233:85–8.
118. Cuevas P, Gimenez-Gallego G. Antiepileptic effects of acidic ﬁbroblast growth
factor examined in kainic acid-mediated seizures in the rat. Neurosci Lett
1996;203:66–8.
119. Sugiura C, Miyata H, Ueda M, Ohama E, Vinters HV, Ohno K. Immunohisto-
chemical expression of ﬁbroblast growth factor (FGF)-2 in epilepsy-associated
malformations of cortical development (MCDs). Neuropathology 2008;
28:372–81.
120. Nistico G, De Sarro G. Behavioral and electrocortical spectrum power effects
after microinfusion of lymphokines in several areas of the rat brain. Ann N Y
Acad Sci 1991;621:119–34.
121. Getts DR, Matsumoto I, Mu¨ller M, Getts MT, Radford J, Shrestha B, et al. Role of
IFN-gamma in an experimental murine model of West Nile virus-induced
seizures. J Neurochem 2007;103:1019–30.
122. Westergaard E, Hertz MM, Bolwig TG. Increased permeability to horseradish
peroxidase across cerebral vessels, evoked by electrically induced seizures in
the rat. Acta Neuropathol 1978;41:73–80.
123. Nitsch C, Klatzo I. Regional patterns of blood-brain barrier breakdown during
epileptiform seizures induced by various convulsive agents. J Neurol Sci
1983;59:305–22.
124. O¨ztas B, Kaya M. The effect of acute hypertension on blood–brain barrier
permeability to albumin during experimentally induced epileptic seizures.
Pharmacol Res 1991;23:41–6.
125. HildebrandtM, Amann K, Schro¨der R, Pieper T, Kolodziejczyk D, Holthausen H,
et al. White matter angiopathy is common in pediatric patients with intrac-
table focal epilepsies. Epilepsia 2008;49:804–15.
126. Tomkins O, Shelef I, Kaizerman I, Eliushin A, Afawi Z,Misk A, et al. Blood–brain
barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry
2008;79:774–7.
127. Tomkins O, Kaufer D, Korn A, Shelef I, Golan H, Reichenthal E, et al. Frequent
blood–brain barrier disruption in the human cerebral cortex. Cell Mol Neuro-
biol 2001;21:675–91.
128. Esen F, Erdem T, Aktan D, Kalayci R, Cakar N, Kaya M, et al. Effects of
magnesium administration on brain edema and blood–brain barrier break-
down after experimental traumatic brain injury in rats. J Neurosurg Anesthesiol
2003;15:119–25.
129. Stolp HB, Ek CJ, Johansson PA, Dziegielewska KM, Potter AM, Habgood MD,
et al. Effect of minocycline on inﬂammation-induced damage to the blood–
brain barrier and white matter during development. Eur J Neurosci
2007;26:3465–74.
130. DiNapoli VA, Huber JD, Houser K, Li X, Rosen CL. Early disruptions of the
blood–brain barrier may contribute to exacerbated neuronal damage and
prolonged functional recovery following stroke in aged rats. Neurobiol Aging
2008;29:753–64.
131. Zucker DK, Wooten GF, Lothman EW. Blood–brain barrier changes with kainic
acid-induced limbic seizures. Exp Neurol 1983;79:422–33.
132. De Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ,
Breimer DD, et al. The inﬂuence of cytokines on the integrity of the blood–
brain barrier in vitro. J Neuroimmunol 1996;64:37–43.
133. Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP
modulate the permeability of an in vitro model of the human blood–brain
barrier. Exp Neurol 2004;190:446–55.
134. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, et al.
Cyclooxygenase inhibition limits blood-brain barrier disruption following
intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol
Exp Ther 2007;323:488–98.
135. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, Hernandez N, et al.
Seizure-promoting effect of blood–brain barrier disruption. Epilepsia
2007;48:732–42.
G. Li et al. / Seizure 20 (2011) 249–256256136. Fabene PF, NavarroMora G,MartinelloM, Rossi B, Merigo F, Ottoboni L, et al. A
role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med
2008;14:1377–83.
137. Van Vliet EA, da Costa Arau´jo S, Redeker S, van Schaik R, Aronica E, Gorter JA.
Blood–brain barrier leakage may lead to progression of temporal lobe epilep-
sy. Brain 2007;130:521–34.
138. Tracey KJ. Understanding immunity requires more than immunology. Nat
Immunol 2010;11:561–4.
139. Tracey KJ. Physiology and immunology of the cholinergic antiinﬂammatory
pathway. J Clin Invest 2007;117:289–96.140. De Herdt V, Bogaert S, Bracke KR, Raedt R, De Vos M, Vonck K, et al. Effects of
vagus nerve stimulation on pro- and anti-inﬂammatory cytokine induction in
patients with refractory epilepsy. J Neuroimmunol 2009;214:104–8.
141. Majoie HJ, Rijkers K, Berfelo MW, Hulsman JA, Myint A, Schwarz M, et al.
Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-
inﬂammatory cytokines in peripheral blood. Neuroimmunomodulation
2011;18:52–6.
142. Corcoran C, Connor TJ, O’Keane V, Garland MR. The effects of vagus nerve
stimulation on pro- and anti-inﬂammatory cytokines in humans: a prelimi-
nary report. Neuroimmunomodulation 2005;12:307–9.
